(Q35172375)

6 August 2017

1 reference

title

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review (English)

1 reference

chronic inflammatory demyelinating polyradiculoneuropathy

6 August 2017

main subject

0 references

1 reference

Ivo N van Schaik

1

1 reference

6 August 2017

John B Winer

series ordinal

2

1 reference

6 August 2017

Rob de Haan

series ordinal

3

1 reference

6 August 2017

Marinus Vermeulen

series ordinal

4

1 reference

6 August 2017

publication date

1 December 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

1

1 reference

6 August 2017

issue

8

1 reference

6 August 2017

page(s)

491-498

1 reference

Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Future developments in the treatment of immune-mediated polyneuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy with only sensory symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Ocular palsy preceding chronic relapsing polyneuropathy by several weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Comparison of electrodiagnostic criteria for demyelination in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Subacute Idiopathic Demyelinating Polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

In vitro effects of polyvalent immunoglobulin for intravenous use.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Randomized trial of interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2802%2900222-3

7 January 2021

10.1016/S1474-4422(02)00222-3

Identifiers

DOI

1 reference

6 August 2017

1 reference